potassium citrate / potassium hydrogen carbonate

This medicine is authorised for use in the European Union.


Sibnayal is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough. This results in a build-up of acid in the blood, which leads to a range of symptoms including hearing and growth problems, vomiting, kidney stones and lack of alertness. The disease also causes levels of potassium in the blood to fall, which can lead to muscle weakness and paralysis.

Sibnayal contains the active substances potassium citrate and potassium hydrogen carbonate.

This EPAR was last updated on 03/05/2021

Authorisation details

Product details
Agency product number
Active substance
  • Potassium citrate monohydrated
  • Potassium hydrogen carbonate
International non-proprietary name (INN) or common name
  • potassium citrate
  • potassium hydrogen carbonate
Therapeutic area (MeSH)
Acidosis, Renal Tubular
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Advicenne S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

22 Rue De La Paix
75002 Paris

Product information

30/04/2021 Sibnayal - EMEA/H/C/005407 -


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Mineral supplements

Therapeutic indication

Sibnayal is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.

Assessment history

How useful was this page?

Add your rating